195 related articles for article (PubMed ID: 19781099)
21. Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Reed SD; Li Y; Leal J; Radican L; Adler AI; Alfredsson J; Buse JB; Green JB; Kaufman KD; Riefflin A; Van de Werf F; Peterson ED; Gray AM; Holman RR;
Diabetes Obes Metab; 2018 Jul; 20(7):1732-1739. PubMed ID: 29573215
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA.
Deitelzweig SB; Lovelace B; Christoph M; Lingohr-Smith M; Lin J; Fermann GJ
Adv Ther; 2020 Sep; 37(9):3942-3953. PubMed ID: 32699994
[TBL] [Abstract][Full Text] [Related]
23. Cost of atrial fibrillation in United States managed care organizations.
Kim MH; Lin J; Hussein M; Kreilick C; Battleman D
Adv Ther; 2009 Sep; 26(9):847-57. PubMed ID: 19768638
[TBL] [Abstract][Full Text] [Related]
24. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes.
Mody R; Kalsekar I; Kavookjian J; Iyer S; Rajagopalan R; Pawar V
J Diabetes Complications; 2007; 21(2):75-83. PubMed ID: 17331855
[TBL] [Abstract][Full Text] [Related]
25. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.
Kim MH; Johnston SS; Chu BC; Dalal MR; Schulman KL
Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):313-20. PubMed ID: 21540439
[TBL] [Abstract][Full Text] [Related]
26. Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S.
Yu S; Fu AZ; Qiu Y; Engel SS; Shankar R; Brodovicz KG; Rajpathak S; Radican L
J Diabetes Complications; 2014; 28(5):621-6. PubMed ID: 24929797
[TBL] [Abstract][Full Text] [Related]
27. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
28. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database.
Feldman SR; Tian H; Gilloteau I; Mollon P; Shu M
BMC Health Serv Res; 2017 May; 17(1):337. PubMed ID: 28482887
[TBL] [Abstract][Full Text] [Related]
29. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
30. Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations.
Annavarapu S; Ghosh S; Li Y; Moretz C; Shetty S; Prewitt T
Am J Manag Care; 2020 Jun; 26(6):e166-e171. PubMed ID: 32549065
[TBL] [Abstract][Full Text] [Related]
31. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial.
Simpson SH; Lier DA; Majumdar SR; Tsuyuki RT; Lewanczuk RZ; Spooner R; Johnson JA
Diabet Med; 2015 Jul; 32(7):899-906. PubMed ID: 25594919
[TBL] [Abstract][Full Text] [Related]
33. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
34. Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population.
Kern DM; Mellström C; Hunt PR; Tunceli O; Wu B; Westergaard M; Hammar N
Curr Med Res Opin; 2016; 32(4):703-11. PubMed ID: 26709864
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
36. Costs and outcomes of noncardioembolic ischemic stroke in a managed care population.
Engel-Nitz NM; Sander SD; Harley C; Rey GG; Shah H
Vasc Health Risk Manag; 2010 Oct; 6():905-13. PubMed ID: 20957133
[TBL] [Abstract][Full Text] [Related]
37. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
[TBL] [Abstract][Full Text] [Related]
38. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
[TBL] [Abstract][Full Text] [Related]
39. Cost estimation of cardiovascular disease events in the US.
O'Sullivan AK; Rubin J; Nyambose J; Kuznik A; Cohen DJ; Thompson D
Pharmacoeconomics; 2011 Aug; 29(8):693-704. PubMed ID: 21585226
[TBL] [Abstract][Full Text] [Related]
40. The costs of treating long-term diabetic complications in a developing country: a study from India.
Kumpatla S; Kothandan H; Tharkar S; Viswanathan V
J Assoc Physicians India; 2013 Feb; 61(2):102-9. PubMed ID: 24471248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
